A RAPID AND CONVENIENT METHOD TO ENHANCE TRANSGENIC EXPRESSION IN TARGET CELLS

Gene therapy provides a novel strategy and a new hope for patients with cancer. Unfortunately, the specifics of the delivery systems or the promoters have not achieved the specified efficacy so far, and the perfection of either system will be extremely difficult. In this study, we introduce a simple concept that a combination of a partially specific delivery system and a partially specific promoter activity may achieve a more specific effect on transgenic expression in target cells. The first section describes tumor-related transcription factors that were assayed in tumors or rapidly proliferating cells to determine their activities. The activities of nuclear factor (NF)-κB, CREB, and HIF-1 were higher, and three copies of each response element were used to construct a transcription factor-based synthetic promoter (TSP). The results showed that the expression of the TSP was active and partially specific to cell types. As described in the second section, the multifunctional peptide RGD-4C-HA was designed to absorb polyethyleneimine (PEI) molecules, and this complex was targeted to integrin αvβ3 on B16F10 cells. The results indicated that RGD-4C-HA could associate with PEI to mediate specific targeting in vitro. Finally, the combination of the PEI–peptide complex and TSP could enhance the specifically transgenic expression in B16F10 cells. This strategy has been proven to work in vitro and might potentially be used for specific gene therapy in vivo.

[1]  X. Qi,et al.  Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy , 2011, International journal of nanomedicine.

[2]  Won Jong Kim,et al.  PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy. , 2011, Oligonucleotides.

[3]  Wing‐Fu Lai.  In vivo nucleic acid delivery with PEI and its derivatives: current status and perspectives , 2011, Expert review of medical devices.

[4]  B. Qin,et al.  Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells , 2010, Breast Cancer Research.

[5]  Wei-Yang Chang,et al.  The characteristics and transfection efficiency of PEI modified by biodegradable poly(β-amino ester) , 2010, Journal of materials science. Materials in medicine.

[6]  M. Bar‐eli,et al.  Silencing cAMP-response Element-binding Protein (CREB) Identifies CYR61 as a Tumor Suppressor Gene in Melanoma* , 2009, The Journal of Biological Chemistry.

[7]  Tomoko Ito,et al.  Highly efficient in vivo gene transfection by plasmid/PEI complexes coated by anionic PEG derivatives bearing carboxyl groups and RGD peptide. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  H. Ghandehari,et al.  Polymeric conjugates of mono- and bi-cyclic αvβ3 binding peptides for tumor targeting , 2006 .

[9]  R. Cristiano,et al.  A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy , 2006, Gene Therapy.

[10]  Y. Kaneda,et al.  Non‐viral vectors for cancer therapy , 2006, Cancer science.

[11]  R. Cristiano,et al.  Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate , 2006, Gene Therapy.

[12]  D. Curiel,et al.  Gene therapy for carcinoma of the breast , 2006, Cancer Gene Therapy.

[13]  H. Ghandehari,et al.  Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[14]  A. Sochanik,et al.  Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model. , 2006, Acta biochimica Polonica.

[15]  R. Schiffelers,et al.  RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[16]  A. Göpferich,et al.  Polyethylenimine-based non-viral gene delivery systems. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  R. Cristiano,et al.  Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13. , 2005, Human gene therapy.

[18]  Rosanna Martinelli,et al.  Short and highly efficient synthetic promoters for melanoma‐specific gene expression , 2005, FEBS letters.

[19]  T. Fujiwara,et al.  [Gene therapy for lung cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[20]  D. Nettelbeck,et al.  Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. , 2004, Molecular cancer therapeutics.

[21]  S J White,et al.  Promoters and control elements: designing expression cassettes for gene therapy. , 2004, Current gene therapy.

[22]  D. Schadendorf,et al.  Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma , 2003, Experimental dermatology.

[23]  Lily Wu,et al.  Transcriptionally targeted gene therapy to detect and treat cancer. , 2003, Trends in molecular medicine.

[24]  D. Hirst,et al.  Transcriptional Targeting in Cancer Gene Therapy , 2003, Journal of biomedicine & biotechnology.

[25]  D. Fischer,et al.  Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[26]  David A. Cheresh,et al.  Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.

[27]  F. McCormick,et al.  Cancer gene therapy: fringe or cutting edge? , 2001, Nature Reviews Cancer.

[28]  K. Harrington,et al.  Transcriptional control: an essential component of cancer gene therapy strategies? , 2000, Advanced drug delivery reviews.

[29]  A. Mikos,et al.  Poly(ethylenimine) and its role in gene delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[30]  A. Mikos,et al.  Improved packing of poly(ethylenimine)/DNA complexes increases transfection efficiency , 1999, Gene Therapy.

[31]  E. Brambilla,et al.  In vivo delivery to tumors of DNA complexed with linear polyethylenimine. , 1999, Human gene therapy.

[32]  W. Silvers,et al.  Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K. Sekiguchi,et al.  Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. , 1995, Biochemistry.

[35]  S. Hart,et al.  Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. , 1994, The Journal of biological chemistry.

[36]  A. Israël,et al.  The DNA binding subunit of NF-κB is identical to factor KBF1 and homologous to the rel oncogene product , 1990, Cell.